Golden Spark Corporation is a limited liability company, registered in California, USA, mainly engaged in extended R&D and marketing & Sales of its newly launched product PLAS. The core technology of the product belongs to Shanghai Spark Pharmaceutical Co., Ltd., a high-tech enterprise registered in the Zhangjiang Hi-Tech Park, Shanghai China, specializing in the application development and therapeutic clinical research of PLAS factor (polyphenolic selenium complex preparations).
The polyphenolic selenium complex (PLAS factor) agent developed by the company currently is a new type of enteric-coated capsules with natural plant-based organic selenium complex. Its selenium content is 10,000 – 100,000 mcg/capsule.
Golden Spark Corporation has accomplished the following tasks since its establishment:
1) Collaborating with Shanghai Spark Pharmaceutical Co., Ltd., Golden Spark Corporation has applied for dozens of domestic and international patents for the core technology.
2) Co-founded “PLAS Joint Laboratory” with Shanghai Advanced Research Institute, Chinese Academy of Sciences, aiming to set up an advanced scientific research laboratory for PLAS factor theory.
3) According to the voluntary and prudence principle of the Helsinki Declaration, the company has undertaken some preliminary application studies on how the PLAS factor helps patients with hepatitis B, HIV, cancer, cardio and cerebrovascular diseases and etc.
4) Successfully registered with the U.S. Food and Drug Administration for dietary supplement. (U.S. FDA Registration No.: 17650460438)
Passion for Innovation
We believe that innovation is key in bringing long-term value for our customers. We aim to provide our customers with solutions to receive positive treatments of diseases while we contribute our knowledge and research into improving the world in the medical field. Actively developing new products, new processes, and new services to customers around the world.
Within the walls of our company, we’ve established an international team of the most talented individuals. Our employees enjoy sharing their creativity and infinite potentials together, in one mission to accomplish higher success. Everyone is treated with respect internally and externally with our business partners.
It is our responsibility to comply with the laws of nature. This is why we’ve built a system to prevent toxic waste during the process our emissions. Economic interests do not override the safety, health, and our environmental factors. We strongly hold our integrity of the company’s values, abiding by the law, and fulfilling the country’s business practices.
Return of Investment
From the business perspective, our focus has always been creating sustainable profitability. Through the enhancement of our performance, we have been able to create additional value for our customers, employers, and shareholders.
The company’s release of the polyphenols selenium dietary supplement PLAS is compounded with natural botanical extracts of polyphenols from the new enteric-coated capsules. The selenium content is 50000mcg / tablet for the prevention and adjuvant treatment of chronic diseases (such as hepatitis, lupus, psoriasis, vitiligo, diabetes, etc.), and has received U.S. FDA approval. The tablet is 2.5 times higher in selenium content than the resveratrol, and the polyphenols are equivalent to a daily dosage of up to 600000mcg.
In addition, the company’s PLAS factor based technology has also developed two new projects for health care products, mainly for major diseases (such as cancer, AIDS) products HIMA, and product PICUS for cardiovascular health, the selenium content is 100000mcg / tablets and 10000mcg / tablets, with the use of the new enteric-coated capsules, each bottle containing 90 capsules.
In the future, the company will continue to develop A class drugs specializing in the treatments of a variety of major diseases, such as cancer, hepatitis B, and AIDS.